Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash

Imatinib remains the standard of care for gastrointestinal stromal tumors (GISTs), serving as the only treatment with proven efficacy in the adjuvant setting and the preferred first-line therapy for metastatic disease (1,2). Maintaining imatinib therapy is essential for optimal disease control and survival, with adjuvant duration up to five years (potentially longer in high-risk forms of the disease). Patients often received indefinite treatment for metastatic GIST sensitive to imatinib, particularly those harboring exon 11 deletion mutations. It has been shown that these patients experience superior outcomes on imatinib therapy [median overall survival (OS) of 66 months] as compared to patients with tumors harboring KIT exon 9 or KIT wild-type status receiving the same drug (OS 38 to 40 months) (2-5).

However, imatinib-associated skin rash can compromise adherence; when severe, this adverse effect can lead to permanent treatment discontinuation, even when the treatment is working efficaciously against cancer growth. Thus, the consequences of interruption are not benign: loss of disease control, resistance, and lower survival. The cost of stopping imatinib is particularly high in the adjuvant setting, because no proven alternative therapies exist. In metastatic disease, the BFR14 trial showed that treatment interruption after three years resulted in rapid progression (median 7.0 vs. 67.0 months with continuation), and inferior survival (104.0 vs. 134.0 months) (6).

Severe imatinib-associated skin rash occurs in approximately 7% of patients receiving the standard dose of 400 mg daily, with increased rates at higher doses (8.9% at 800 mg daily); notably, a single-center series described higher incidences (37%) in patients receiving an intermediate dose of 600 mg daily (7-9).

This brings up a familiar clinical dilemma: when a highly effective and difficult-to-replace therapy is complicated by severe toxicity, should treatment be restarted, and if so, how can this rechallenge be undertaken safely without compromising efficacy?

Current management focuses on symptomatic measures and corticosteroids, often accompanied by temporary treatment interruption. However, these approaches have been informed mainly by small studies and case reports. The field has lacked a standardized approach for re-introducing imatinib in this setting.

In this context, the personalized desensitization strategy reported by Liu and colleagues, which integrates stepwise dose re-escalation with therapeutic drug monitoring (TDM) (as shown in Figure 1) offers a pragmatic framework to resume imatinib while reducing the risk of subtherapeutic exposure. The high rate of treatment continuation with this approach is compelling, with 92.6% of patients successfully resuming imatinib despite prior severe cutaneous toxicity. This approach operationalizes a critical principle: treatment-limiting toxicities can be mitigated without sacrificing the pharmacologic intensity that sustains durable disease control (10).

Figure 1 Desensitization therapy for imatinib-associated severe skin rash. Adapted from Liu X, Pi M, Chen M, et al. The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation. The Oncologist 2025;30:oyaf176. (10). IM, imatinib; PPI, proton pump inhibitor; Q.M., every morning; TDM, therapeutic drug monitoring.

The study has many strengths. This large retrospective study of 712 patients treated with imatinib, among whom 54 (7.6%) developed severe skin rash, represents the largest study focused specifically on the management of imatinib-associated severe rash. It is distinctive in its integration of TDM and pharmacogenetic analysis in patients with this toxicity.

Prior strategies have been limited. A phase II study evaluated continuation of imatinib using oral prednisolone 30 mg daily for 3 weeks, followed by a 12-week taper, achieving a response in 75.8% of patients. However, the study was constrained by the absence of a comparator arm, small sample size, recurrent severe rash in nearly 25% of patients, and safety concerns related to prolonged steroid exposure. Other approaches, including slow desensitization protocols and an isolated case report using doxycycline and clemastine, have been based on very limited patient numbers. While these strategies allowed re-escalation of imatinib to conventional target doses (up to 400 mg daily) despite cutaneous toxicity, they do not establish a clear dose-toxicity relationship. Available data do not consistently support a simple dose-dependent mechanism for imatinib-associated rash. Emerging evidence suggests that interpatient variability in drug exposure may be more relevant than nominal dose alone. These prior approaches, therefore, lack a structured, exposure-informed framework that accounts for pharmacokinetic variability and individualized toxicity risk—a gap addressed by Liu and colleagues (10-13).

A key strength is the use of a minimum therapeutic trough concentration (>738 ng/mL), providing a structured, exposure-informed framework that seeks to balance safety with efficacy. However, the choice of trough threshold raises important questions. Historically, target imatinib trough concentrations of >1,100 ng/mL have been associated with optimal outcomes in Western populations, while prior studies have shown data regarding a range of lower thresholds (760–950 ng/mL). Emerging data suggest that optimal exposure may be mutation-specific. Patients with KIT exon 11 mutations may achieve a benefit at lower concentrations (>680 ng/mL) whereas patients with KIT exon 9 mutations may require substantially higher exposure (>1,877 ng/mL). These differences, coupled with population-level variability in pharmacokinetics, argue against a one-size-fits-all threshold (14-19). In the context of severe toxicity, the central unanswered question becomes what degree of exposure is sufficient to maintain long-term benefit while minimizing toxicities and their recurrence. For mixed patient populations, a target trough of 1,100 ng/mL may represent a reasonable compromise, whereas exon 9-mutant disease may need a more individualized approach.

One important pharmacokinetic consideration is the potential impact of prolonged corticosteroid use on imatinib clearance. Corticosteroids induce cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), the primary pathways for imatinib metabolism. At the same time, imatinib is a potent mechanism-based inhibitor of CYP3A4 at steady state, creating competing effects: corticosteroid-mediated induction versus imatinib-mediated autoinhibition. This interplay may produce substantial variability in systemic drug exposure, particularly during corticosteroid tapering when inductive effects diminish (20).

Steroid-related adverse events were observed in 9.5% of patients, including soft tissue infections, hyperglycemia, and one case of duodenal ulcer (despite proton pump inhibitors) associated with prolonged corticosteroid exposure following multiple rash recurrences. While the overall safety profile appears acceptable, these emphasize the need for careful monitoring and, in selected cases, multidisciplinary supportive care to mitigate cumulative steroid-related toxicity.

An additional clinically relevant observation is the earlier onset of grade 3 rash compared with recurrent grade 2 toxicity, reinforcing the importance of heightened vigilance during the initial phase of imatinib therapy. Early identification of patients at risk for severe rash may inform the intensity and timing of monitoring.

The pharmacogenetic signal involving the IL-6R variant is notable but does not yet appear to be practice-changing. The association between rs4129267 and severe rash [odds ratio 1.97, 95% confidence interval (CI): 1.14–3.38; P=0.015] remains statistically significant after appropriate Bonferroni correction, and the biological plausibility of IL-6-mediated inflammatory pathways lends credibility to the finding. Nevertheless, the absence of performance metrics such as sensitivity, specificity, or predictive values, precludes immediate clinical implementation. At present, this robust signal should be viewed as hypothesis-generating rather than actionable.

Several limitations warrant consideration. This was a retrospective, single-center analysis, and while TDM enhances implementation, the study does not establish that TDM independently improves desensitization outcomes compared with desensitization alone. Additionally, this approach should not be extrapolated to life-threatening cutaneous adverse reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis, where permanent discontinuation remains mandatory. From a practical standpoint, the feasibility of TDM-guided desensitization is constrained by limited access and interlaboratory variability, supporting implementation primarily in experienced, high-volume centers.

In summary, in patients who develop severe imatinib-associated skin rash, a personalized desensitization approach assisted by TDM offers a rational, exposure-informed strategy to preserve treatment continuity while minimizing toxicities. Although pharmacogenetic findings remain exploratory, this framework represents a pragmatic step toward precision toxicity management. Prospective studies validating standardized protocols, defining actionable exposure thresholds, and prioritizing long-term clinical outcomes will be essential. Until then, for patients in whom continued imatinib therapy is critical, especially for those molecularly predicted to benefit from imatinib the most, this approach warrants consideration and potential implementation at experienced centers for patients to maintain both disease control and quality of life.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article has undergone external peer review.

Peer Review File: Available at https://jgo.amegroups.com/article/view/10.21037/jgo-2026-0174/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2026-0174/coif). E.L. reports consulting fees as an advisor for Myer Research, Inc. and paid consultant for Primum; honoraria from Medscape, Georgia Cancer Specialists, and Impiricus, as well as compensation for scientific review from Elsevier Publishing and Johns Hopkins Press; research/support grants from the American Cancer Society (RSG-22-022-01-CDP, 2022–2026) and the University of Minnesota/NIDDK-funded CPDPC consortium (5U01DK126300-03); travel support from the University of Minnesota; financial interests in Ryght, Inc.; equipment for laboratory-based research from Novocure, Ltd. (2018–present); and an unpaid leadership role as past chair of the Education Committee of the North American Neuroendocrine Tumor Society, with no royalties, patents, expert testimony fees, or advisory/DSMB participation. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Balachandran VP, DeMatteo RP. Gastrointestinal stromal tumors: who should get imatinib and for how long? Adv Surg 2014;48:165-83. [Crossref] [PubMed]
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013;382:973-83. [Crossref] [PubMed]
3. Raut CP, Espat NJ, Maki RG, et al. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol 2018;4:e184060. [Crossref] [PubMed]
4. Joensuu H, Eriksson M, Sundby Hall K, et al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol 2020;6:1241-6. [Crossref] [PubMed]
5. Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of the phases III SWOG intergroup trial S0033. JAMA Oncol 2017;3:944-52. [Crossref] [PubMed]
6. Blay JY, Devin Q, Duffaud F, et al. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2024;25:1163-75. [Crossref] [PubMed]
7. Casali PG, Zalcberg J, Le Cesne A, et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol 2017;35:1713-20. [Crossref] [PubMed]
8. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32. [Crossref] [PubMed]
9. Lee WJ, Lee JH, Won CH, et al. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib. Int J Dermatol 2016;55:e268-74. [Crossref] [PubMed]
10. Liu X, Pi M, Chen M, et al. The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation. Oncologist 2025;30:oyaf176. [Crossref] [PubMed]
11. Kim EJ, Ryu MH, Park SR, et al. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. Oncologist 2020;25:e1785-93. [Crossref] [PubMed]
12. Klaewsongkram J, Thantiworasit P, Sodsai P, et al. Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4(+)CD25(+)CD134(+) lymphocytes. Ann Allergy Asthma Immunol 2016;117:514-9. [Crossref] [PubMed]
13. Desar IM, van Herpen CM, van Erp NP, et al. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. Anticancer Drugs 2016;27:576-9. [Crossref] [PubMed]
14. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable or metastatic gastrointestinal stromal tumors. J Clin Oncol 2009;27:3141-7. [Crossref] [PubMed]
15. Bouchet S, Poulette S, Titier K, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer 2016;57:31-8. [Crossref] [PubMed]
16. Xu T, Xie J, Jiang C, et al. Unveiling the impact of adherence: imatinib plasma levels and survival in postoperative gastrointestinal stromal tumor patients. Br J Cancer 2025;133:1307-16. [Crossref] [PubMed]
17. Teranishi R, Takahashi T, Nishida T, et al. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST. Int J Clin Oncol 2023;28:680-7. [Crossref] [PubMed]
18. Xia Y, Zhang X, Jiang A, et al. Correlation between imatinib trough concentration and efficacy in patients with advanced GIST with different genotypes. J Clin Oncol 2024;42:e23515.
19. Zhang M, Chen Z, Liu X, et al. Study of genetic polymorphisms and steady-state trough concentrations of imatinib and its active metabolite in predicting efficacy in gastrointestinal stromal tumors. Front Pharmacol 2025;16:1604619. [Crossref] [PubMed]
20. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003;18:2409-14. [Crossref] [PubMed]